TG Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report3 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
TG Therapeutics, Inc.
61.64
−11.26%
vs ±11.4% implied · ×0.99
shaded = implied · ▲▼ = realized
TG Therapeutics has 6 disclosed suppliers and 1 disclosed customer in SEC filings.
SentenceAlthough Precision BioSciences, Inc. terminated its SPL agreement subsequent to its announced license of the Azercabtagene Zapreleucel (azer-cel) program to Imugene Limited and TG Therapeutics, Inc., both Imugene (USA), Inc. and TG Therapeutics, Inc. have since entered into SPL agreements with MaxCyte for azer-cel.
SentenceWe have established a contract manufacturing relationship with Samsung Biologics for our primary clinical and commercial supply of BRIUMVI, and a secondary contract manufacturing relationship with FUJIFILM Diosynth Biotechnologies.
TGTX 10-Kaccession 0001437749-26-006133
SentencePursuant to our license agreement with Precision, we have an exclusive license to develop and commercialize Precision's azer-cel for the treatment of autoimmune and other non-oncology diseases and conditions as well as a non-exclusive license to manufacture azer-cel.
TGTX 10-Kaccession 0001437749-26-006133
SentenceWe have established a contract manufacturing relationship with Samsung Biologics for our primary clinical and commercial supply of BRIUMVI, and a secondary contract manufacturing relationship with FUJIFILM Diosynth Biotechnologies.
TGTX 10-Kaccession 0001437749-26-006133
SentenceThe cost of revenue for the years ended December 31, 2024 and December 31, 2023 includes $2.4 million and $1.5 million, respectively, of costs related to delivering regulatory support and development services to Neuraxpharm in accordance with the Commercialization Agreement.
TGTX 10-Kaccession 0001437749-26-006133
Linked news
Expected move
Inputs8Q avg ±11.2%·×1.05·fair
straddle ±14.1%
spot 61.18exp Nov 20ATM strike 60ATM straddle 10.15IV 87%